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1 Summary 
The natural transmission routes of the three feline hemotropic mycoplasmas, 
Mycoplasma haemofelis, ,Candidatus Mycoplasma haemominutum’, and 
,Candidatus Mycoplasma turicensis’ (CMt), are largely unknown. Since saliva 
of CMt-infected cats has been found to be PCR-positive, we hypothesized that 
direct transmission via social or aggressive contact may occur. The aim of our 
study was to evaluate these transmission routes. For this purpose, five SPF 
cats received CMt-positive saliva or blood inoculi subcutaneously to mimic cat 
bites whilst another five cats received the inoculi orally (blood)/oronasally 
(saliva) to mimic social contact. Blood samples were monitored for CMt 
infection using quantitative real-time PCR and for seroconversion by a novel 
Western blot assay. Neither oral nor subcutaneous inoculation of CMt-positive 
saliva led to CMt infection as determined by PCR in the recipient cats 
independent of the presence of immunosuppression. When infectious blood 
containing the same CMt dose was given subcutaneously, four of the five cats 
became PCR-positive, while none of the five cats inoculated orally with up to 
500 µl of infectious blood became PCR-positive. Subsequently, the latter cats 
were successfully subcutaneously infected with blood. All CMt exposed cats 
seroconverted. In conclusion, CMt transmission by social contact seems highly 
unlikely, whilst transmission via aggressive interaction (cat bites) may occur if 
the recipient cat is exposed to infectious blood.  
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2 Introduction 
Three hemotropic mycoplasmas, the causative agents of feline infectious 
anemia, have been differentiated in cats: Mycoplasma haemofelis (Mhf), 
previously ascribed to the genus Haemobartonella, ,Candidatus M. 
haemominutum’ (CMhm) and ,Candidatus M. turicensis’ (CMt) (10, 32, 34, 37, 
46). Another hemotropic mycoplasma, similar to the canine hemotropic 
mycoplasma ,Candidatus M. haematoparvum’, has also been suggested to 
occur in cats (38). Their pathogenic potential varies. Immunosuppression or 
preexisting retroviral infections may potentiate the severity of anemia (2, 14, 
17, 36, 46). 
The diagnosis of feline hemotropic mycoplasmas (aka hemoplasmas) had 
been limited because microscopic detection of the agents on blood smears 
was unreliable (40, 45). Recently, sensitive TaqMan real-time PCR assays 
have been introduced and are now considered to be the gold standard for 
detection and differentiation of all three species (42, 45, 46). Using PCR, a 
worldwide distribution of feline hemotropic mycoplasma infections in felids has 
been documented (3, 12, 27, 29, 30, 40, 41, 44, 49). So far, no commercial 
routine serologic assay for feline hemoplasmas is available. Serodiagnostics 
have depended on crude Mhf antigens, either purified from the blood of 
experimentally infected cats or present on blood smears from acutely infected 
cats, as a substrate for indirect fluorescent antibody assays (1, 9). Results of 
immunoblotting and immunofluorescence assays using antigenically undefined 
blood extracts showed that anti-Mhf antibodies were detectable two to three 
weeks post infection (p.i.) (1, 9). Lately, an immunodominant protein of 
Mycoplasma suis, the porcine hemoplasma species, was identified as HspA1, 
a surface-localized dnaK-analogous protein by serological proteome analysis 
and screening of a genomic M. suis library (23-25).  
The natural mode of transmission of feline hemoplasmas has been under 
investigation for many years but is still controversial. Transmission by 
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experimental blood inoculation via the intraperitoneal, intravenous and oral 
routes has been successful (8). In addition, transplacental and lactogenic 
transmission have been discussed (6, 16, 20). However, these studies had 
been performed prior to the introduction of specific molecular assays. Blood 
transfusions have been reported to be effective in hemoplasma transmission 
(13, 19, 45). Furthermore, blood-sucking arthropods might be involved in the 
transmission of feline hemoplasmas in certain regions. Unfed ticks in Japan 
but not in Switzerland were found to be PCR-positive for feline hemoplasmas 
(39, 47). The cat flea Ctenocephalides felis is also thought to be a vector but 
transmission has not been proven (50, 51). Moreover, the low prevalence of 
feline hemoplasmas in fleas and ticks in Switzerland contradicted the 
hypothesis of arthropods being the major vector at least in this geographical 
region (47). Because of the close phylogenetic relationship of CMt and rodent 
hemotropic mycoplasmas (M. coccoides and M. haemomuris) an interspecies 
transmission of hemoplasmas between rodents and cats was suggested but 
could not be proven so far (46, 47). 
Most recently, the investigation of shedding patterns by real-time PCR showed 
CMt shedding in saliva and feces (4, 47) and we hypothesized that feline 
hemoplasmas could be transmitted by direct contact (social or aggressive) via 
saliva (47). Our hypothesis is supported by an increased occurrence of 
hemoplasma infections in male cats and cats with a history of cat bite 
abscesses (17, 21, 30, 40, 45).  
The aim of the present study was to address this hypothesis and investigate 
the possible direct transmission of CMt between cats. To mimic aggressive 
contact and cat bites, saliva or blood samples from CMt-infected cats were 
inoculated subcutaneously to recipient cats, whilst social contact between cats 
was simulated by oronasal and oral inoculation. All cats were monitored after 
CMt exposure and blood samples were assessed for CMt infection using 
sensitive real-time PCR and a novel Western blot assay. 
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3 Materials and Methods 
3.1 Cats 
Thirteen specific pathogen free (SPF) cats (Liberty Research Inc., Waverly, 
NY, USA) were included in the study. They were kept in a confined university 
facility in groups under etiologically and hygienically ideal conditions. Prior to 
the start of the experiment, each cat was clinically examined and blood, 
conjunctival, oropharyngeal, and rectal swabs were collected from all cats to 
verify their SPF status. The cats were found to be negative when the samples 
were tested for the three feline hemoplasmas, feline coronavirus, feline 
calicivirus, feline herpesvirus-1, Chlamydophila felis, feline parvovirus, 
Bartonella henselae, feline leukemia virus, and feline immunodeficiency virus 
by real-time TaqMan PCR or reverse transcription-PCR and by serology for 
antibodies to the feline corona virus as previously reported (18, 22, 26, 28, 31, 
33, 35, 43, 45). Cats were blood typed by a commercial gel column technique 
for determination of the feline blood types A, B and AB (ID-Gel Test Feline 
A+B Typing; DiaMed AG, Cressier sur Morat, Switzerland): 11 cats were of 
blood-type A and two cats had blood-type B. Of the 13 cats, three adult male 
castrated cats (two and three years of age), were infected intraperitoneally 
with CMt to obtain infectious saliva and blood samples (amplificatory cats, 
Cats X, Y, and Z). Ten juvenile cats (two months of age), housed in two 
groups of five cats each, were used as the recipient cats for the transmission 
studies. 
 
3.2 Clinical examination, sample and inoculi collection 
Clinical examination was performed by a veterinarian at least twice a week 
and cats were controlled daily by the animal keeper. Complete hemograms of 
the amplificatory cats were performed prior to immunosuppression and prior to 
CMt infection, daily during saliva collection and sporadically until 167 days p.i. 
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for Cats X and Y and until 119 days p.i. for Cat Z. Saliva swabs (Primella, 
Migros Genossenschafts-Bund, Zurich, Switzerland) of the amplificatory cats 
were collected every day once the cats had turned blood PCR-positive by 
placing swabs sublingually and in the cheek pouches. For collection of large 
volumes of saliva for the transmission study, saliva production was stimulated 
by a subcutaneous injection of neostigmine (Valeant Pharmaceuticals, 
Birsfelden, Switzerland; 0.5 mg/kg) 10 minutes prior to ketamine/midazolam 
narcosis (ketamine 20 mg/kg and midazolam 0.1 mg/kg, i.m.; Vétoquinol, 
Ittigen, Switzerland/Roche, Reinach, Switzerland). Saliva samples were 
divided into aliquots for infection and PCR. Saliva was collected in 2 ml 
syringes, placed in Eppendorf tubes and divided into aliquots for infection and 
PCR. 
EDTA-anticoagulated blood samples and serum were collected regularly from 
the ten recipient cats prior to and regularly after CMt exposures for PCR 
analysis, hematology and Western blot analysis. Body temperature and body 
weight were recorded at each sampling date. For humane reasons, cats were 
given supportive care (infusions, analgesics) when required. 
 
3.3 Hematology and biochemistry 
Hemograms consisting of packed cell volume (PCV), hemoglobin (Hb), 
erythrocyte count, mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), mean corpuscular volume (MCV) and total 
leukocyte count were performed using a Cell-Dyn 3500 (Abbott, Baar, 
Switzerland). PCV values between 33 % and 45 % (5% and 95% quantiles, 
reference range of the Clinical Laboratory) were considered to be within the 
normal range; anemia was defined as a PCV value below 33 %. Modified 
Wright-stained blood smears were prepared from fresh EDTA-anticoagulated 
blood using an AMES Hema Tek slide stainer (Bayer, Zurich, Switzerland), 
Diff-Quick® (Medion Diagnostics, Düdingen, Switzerland) stained smears were 
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prepared from EDTA-anticoagulated and native blood. All smears were 
microscopically evaluated for CMt. A serum biochemistry profile was 
performed if clinically indicated using a Cobas Integra 700 instrument (Roche 
Diagnostics, Rotkreuz, Switzerland). 
 
3.4 Intraperitoneal infection 
To obtain fresh infectious saliva and blood samples, the three amplificatory 
cats were infected by intraperitoneal administration of CMt as described 
previously (7). Cats X, Y and Z received 9 x 105 copies of CMt in 0.9 to 1 ml of 
heparinized blood preserved in 20 % DMSO (Sigma-Aldrich, Buchs, 
Switzerland) at -80°C. All three cats were immunocompromised by two 
intramuscular administrations of methylprednisolone acetate (10 mg/kg, Depo-
Medrol ad us. vet., Pfizer AG, Zurich, Switzerland): Cats X and Y were injected 
16 and 9 days prior to CMt inoculation; Cat Z received methylprednisolone 8 
and 1 days prior to CMt inoculation. Additionally, Cat Z received prednisolone 
orally (4 mg/kg/d, Streuli Pharma AG, Uznach, Switzerland) for 20 days 
starting 14 days p.i..  
During Cats X, Y, and Z’s peak bacteremia 40 ml of blood and 2 ml of bone 
marrow were collected. Bone marrow aspirates were obtained from the 
proximal humerus under general anesthesia (ketamine and midazolame) or 
acepromazine 0.1 mg/kg and propofol (induction 5 mg/kg; maintenance 1 
mg/kg when required (Arovet AG, Zollikon, Switzerland/Fresenius KABI Ag, 
Stans, Switzerland)) and analgesia (buprenorphine, 0.01 mg/kg, Essex 
Chemie, Luzern, Switzerland). The bone marrow aspiration needle (Rosenthal 
type, 16 G x 2”, Tyco Healthcare Group LP, Mansfield, U.S.A.) was introduced 
through a small skin incision, the muscle and the bone cortex into the bone.  
Subsequently the three amplificatory cats underwent antibiotic treatment. In 
Cats X and Y, antibiotic treatment with marbofloxacin (Vétoquinol, Ittigen, 
Switzerland) was started at 2 mg/kg q24h for a total of 10 days 41 days p.i.. 
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Afterwards, marbofloxacin was replaced by doxycycline (Grünenthal GmbH, 
Mitlödi, Switzerland) 5 mg/kg q12h for a total of 14 days. Cat Z was treated 
with doxycycline 10 mg/kg q24h for 14 days starting at day 41 p.i.. 
 
3.5 Oronasal and subcutaneous exposure to CMt DNA containing 
saliva 
As a model for direct transmission via saliva and to simulate aggressive and 
social contact, saliva from the CMt-positive amplificatory cats was inoculated 
orally or subcutaneously into the recipient cats within 20 minutes of collection. 
Five recipient cats (group A) were exposed oronasally to saliva (Table 1, A I.). 
The cats each received a cumulative dose of 2 ml of saliva containing 8 x 102 
copies of CMt over 19 days. An aliquot of 100 µl of saliva containing 1 x 102  
copies of CMt was inoculated subcutaneously to each of the five recipient cats 
of group B (Table 1, B I.).  
When inoculations A I. and B I. were unsuccessful, the cats were 
immunosuppressed orally with prednisolone prior to and during the next CMt 
inoculation as indicated in Table 1 (A II. and B II.). Development of saliva-
associated abscesses necessitated termination of immunosuppression in 
group B, and amoxicillin-clavulanate treatment (Synulox, 25 mg/kg, q12h for 9 
days, Pfizer AG) in Cat 7. 
 
3.6 Oral and subcutaneous exposure to CMt containing blood  
Because the salivary inoculations with or without immunosuppression did not 
lead to CMt infection in the recipient cats as determined by real-time PCR, 
cats of both groups A and B were then inoculated with infectious blood (Table 
1, A III. and B III.). The blood aliquots used for inoculation contained the same 
copy number administered previously via saliva (Table 1, A III. and B III.).  
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Each cat of group A ingested 63 µl of blood containing 8 x 103 copies of CMt 
voluntarily by licking (Table 1, A III.). For this group, the monitoring period was 
prolonged to two months as an incubation period of up to 51 days for oral 
transmission was described by Flint (7). However since the cats remained 
PCR-negative despite this prolonged monitoring period, they were 
subsequently inoculated with a larger blood volume of 500 µl (Table 1, A IV.). 
When the cats of group A remained PCR-negative after oral and oronasal 
exposures to saliva, they were challenged subcutaneously with 50 µl of CMt-
positive blood (Table 1, A V.) in order to confirm that the cats could be infected 
with CMt. To simplify subcutaneous injection each aliquot of infectious blood 
was diluted in heparinplasma of the same cat prior to infection to a total 
volume of 100 µl. 
Group B cats received 1 x 103 CMt copies in 10 µl of blood subcutaneously 
(Table 1, B III.). One cat, Cat 7, that remained PCR-negative, was inoculated 
again in exactly the same way 103 days after the first subcutaneous 
inoculation (Table 1, B IV.). 
 
3.7 TNA extraction 
Total nucleic acids (TNA) were extracted from 100 µl of EDTA-anticoagulated 
blood using the MagNa Pure LC Total Nucleic Acid Isolation Kit I (Roche 
Diagnostics). Negative controls consisting of 200 µl phosphate buffered saline 
were prepared with each batch. The DNA was eluted in 100 µl of elution 
buffer. Saliva samples and the saliva swabs in PBS were heated at 40°C for 
10 minutes, centrifuged twice at 6,600 x g for 1 minute before TNA was 
extracted with a MagNa Pure LC total nucleic acid isolation kit (Roche 
Diagnostics) as previously described (15). 
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3.8 Quantitative real-time PCR assay 
All TNA samples were analyzed by real-time TaqMan PCR for the presence of 
CMt DNA as described previously (46). Water was used as a negative control. 
Positive control samples were included in each run. For absolute 
quantification, all positive blood samples were reanalyzed with a plasmid 
standard containing the cloned 16S rRNA gene of CMt (46) diluted tenfold. 
3.9 Serology 
A recombinant HspA1 protein of Mhf was expressed in E. coli. The partial 
sequence of the HspA1 protein of Mhf was obtained using consensus primers 
derived from the HspA1 nucleotide sequence of M. suis (#AM265536) and 
other mycoplasmas (M. penetrans, M. pneumoniae). The 899 bp-fragment was 
ligated into the pQE-30 Xa Vector (Qiagen, Hombrechtikon, Switzerland), 
which was then transformed into E. coli Top10 (Invitrogen, Basel, Switzerland). 
Protein production, SDS-PAGE and immunoblotting were performed as 
described previously (23) with the following modifications. The expression was 
induced by 1 mM IPTG. Recombinant E. coli cultures were grown in LB 
medium supplemented with 100 µg/ml ampicillin. The 6xHis-tagged protein 
was purified by nickel affinity chromatography (Qiagen, Hombrechtigkon, 
Switzerland) or chelating sepharose (GE Health care biosciences, Uppsala, 
Sweden). 10 µg of the antigen were loaded per well in the gel and feline 
serology samples were incubated at a dilution of 1:100. Immunoreactive 
proteins were visualized using horseradish peroxidase-labeled goat anti-cat 
IgG (Sigma Aldrich) as secondary antibodies and 4-chloro-1-naphtol as the 
chromogenic reagent.  
The Western blot was evaluated with samples from four SPF cats infected with 
Mhf (6 weeks p.i.), CMhm (21 weeks p.i.) or CMt (8 weeks p.i.), and from 18 
hemoplasma-free SPF cats. To study seroconversion after CMt infection, the 
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three amplificatory and the ten recipient cats were tested prior to and at 
various time-points after CMt exposure. 
 
3.10 Statistics 
Data were compiled in Excel (Microsoft) and statistical analyses were 
performed using the Excel add-in Analyse-it (Analyse-it Software, Leeds, UK) 
and the Graph-Pad Prism (GraphPad Software, San Diego, CA, USA). For 
correlation analyses the Spearman rank correlation test was used. CMt blood 
loads, PCV values and the duration between CMt exposure and the first PCR-
positive result were analyzed for significant differences among three groups of 
cats using the Kruskal-Wallis test (pKW) and the Dunn’s multiple comparison 
post-test. Analyses between two groups were conducted using the Mann-
Whitney U-Test (pMWU). A p-value <0.05 was considered to be significant. 
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4 Results 
4.1 Characteristics of cats infected intraperitoneally with CMt 
All three amplificatory cats inoculated intraperitoneally with CMt became 
infected. DNA of CMt was detected in blood samples, salivary swabs and bone 
marrow collected from all three cats (Fig. 1). All extraction and the negative 
PCR controls of the entire study tested PCR-negative. Cats X and Z became 
blood PCR-positive at the first sampling date, 6 and 4 days p.i. respectively, 
Cat Y became blood PCR-positive at the sampling on day 11 p.i. (Fig. 1). Peak 
CMt blood loads reached 106 copies/ml of blood whilst bone marrow loads 
reached 104 copies/ml in all three cats. The cats remained PCR-positive in the 
blood until treatment (see below). Cats X, Y, and Z became anemic with 
minimum PCVs of 23%, 29%, and 21% at 18, 19, and 11 days p.i., 
respectively (Fig. 1A, B, and C). When the combined data from the three cats 
were analyzed, hemoplasma loads were negatively correlated with PCV 
values (r = -0.35; p = 0.0057), the erythrocyte counts (r = -0.42; p = 0.0008) 
and the hemoglobin values (r = -0.32; p = 0.0139). This was mainly due to a 
strong correlation found in Cat Z. When the data from latter cat were analyzed 
individually, the following inverse correlations with CMt load were found: PCV 
(r = -0.63; p = 0.0028), erythrocyte count (r = -0.70; p = 0.0006), hemoglobin (r 
= -0.66; p = 0.0016). Significant correlations, or trends towards significance, 
were found in some cats for other erythrocyte indices and high hemoplasma 
loads: high MCH (Cat X: r = 0.60; p = 0.0054) and MCV values (Cat X: r = 
0.43; p = 0.0559; Cat Z: r = -0.57; p = 0.0092), but the indices were never 
found to go beyond reference limits. Mild inappetence and apathy were 
observed in all three cats two to three weeks p.i.. 
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4.2 CMt shedding via saliva  
PCR-positive results were obtained for 15 of 22 salivary swabs collected from 
Cat X, for 11 of 19 salivary swabs collected from Cat Y and for 16 of 26 
salivary swabs collected from Cat Z (Fig. 1). The CMt loads in PCR-positive 
saliva samples ranged from 1 x 102 to 6 x 103 copies per ml of saliva (median: 
7 x 102 copies/ml). 
 
4.3 Transmission experiment: oronasal and subcutaneous exposure to 
CMt DNA containing saliva  
No evidence of CMt infection as determined by real-time PCR was detected in 
any of the recipient cats after attempted transmission of CMt via saliva (up to 7 
x 103 copies oronasally and 1 x 103 copies subcutaneous, respectively). 
Results were identical regardless of the presence or absence of preexisting 
immunosuppression in the ten cats (Table 2, A I. and II. and B I. and II.). 
 
4.4 Transmission experiment: oral and subcutaneous exposure to CMt 
containing blood  
Neither low dose (63 µl) nor high dose (500 µl) oral exposure to CMt-positive 
blood led to infection of the five recipient cats of group A (Tables 1 and 2, A III. 
and A IV.). These cats were subsequently inoculated subcutaneously with 
CMt-infectious blood: they all turned blood PCR-positive between 14 and 45 
days p.i. and developed peak CMt blood loads of 103 to 105 copies/ml of blood 
(Table 2, A V.; Fig. 2 A to E). 
In group B, four of five recipient cats subcutaneously inoculated with CMt 
infectious blood (Table 1, B III.) became blood PCR-positive after an average 
of 22 days (range: 19 - 33 days) with loads ranging from 103 to 105/ml at peak 
bacteremia (Table 2, Fig. 2 F to K). One cat, Cat 7, that had received antibiotic 
treatment for a saliva-associated abscess 30 to 22 days prior to inoculation of 
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blood, remained blood PCR-negative throughout the study. Cat 7 was one of 
the two cats with blood-type B. 
Clinical signs, i.e. fever and weight-loss were absent in the ten recipient cats 
inoculated with infectious blood. Anemia (PCV < 33%) was only observed in 
one case (Cat 1, group A), where the PCV dropped from 37 % to 28% 
coinciding with the peak CMt load of 9 x 105 copies/ml (Fig. 2 A). Similarly, the 
peak bacteremia in Cats 3 and 10 was accompanied by a slight decrease in 
PCV of 7% (group A, Fig. 2 C and 2 K). 
 
4.5 Comparison of experimental infections 
A significant difference in maximum CMt blood loads was observed between 
the amplificatory cats, cats of groups A and cats of group B (pKW = 0.0436). 
The intraperitoneally infected cats (amplificatory cats) showed significantly 
higher loads when compared to subcutaneously exposed recipient cats 
(groups A and B; pMWU = 0.0091; Fig. 3A). A significant difference was also 
found in the duration between CMt exposure and the first PCR positive result 
between the three groups (pKW = 0.0229) and intraperitoneally infected cats 
became PCR-positive earlier after CMt exposure than subcutaneously infected 
cats (pMWU = 0.0091; Fig. 3B). In addition, intraperitoneally infected cats had 
lower minimum PCV values than subcutaneously exposed cats (pMWU = 
0.0182; Fig. 3C). 
 
4.6 Correlation of anemia with CMt loads  
When all CMt PCR-positive cats (n = 12) were included in the analyses, the 
minimum PCV values were significantly negatively correlated with maximum 
CMt blood loads (r = -0.84; p = 0.0006; Fig. 4A). Moreover, the minimum PCV 
was significantly positively correlated with duration between CMt inoculation 
and first PCR-positive blood result: the shorter the incubation period, the lower 
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the minimum PCV (r = 0.80; p = 0.0017; Fig. 4B). In addition, peak CMt blood 
loads were significantly negatively correlated with the incubation period (r =     
-0.86; p = 0.0003; Fig. 4C). 
 
4.7 Serology 
The antigen used in the Western blot assays (Mhf HspA1 fragment) was 
recognized by sera from cats infected with Mhf, CMhm and CMt (calculated 
specific band of 33.6 kDa), while sera from 18 hemoplasma-free SPF cats 
were all negative (Fig. 5A and 5B).  
All cats used in the CMt transmission study were seronegative before CMt 
exposure. After CMt challenge, all 13 (amplicatory and recipient) cats became 
positive in Western blot analyses (Fig. 5B and 5C). Weekly investigations of 
serum samples demonstrated seroconversion in the majority of the cats 
between three and four weeks p.i. (Figs. 1 and 2).  
In intraperitoneally CMt infected cats, seroconversion occurred between three 
to six weeks p.i. (Fig. 1). Cats remained seropositive until 13 to 15 weeks p.i.. 
Thereafter the bands in the Western blot assay decreased visually in intensity. 
In group A, four out of five cats had seroconverted three to four weeks after 
exposure A V. (Fig. 2A and C-E), while one cat, Cat 2 (Fig. 2B) had already 
seroconverted at the start of this experiment, i.e. seven weeks after oronasal 
inoculation of saliva (A II.). Cat 2 was the second of the two cats with blood-
type B.  
In group B, the four PCR-positive cats also seroconverted after CMt exposure 
(Table 2, B III.) between 3 and 5 weeks p.i. (Fig. 2F, H, I and K). One cat, Cat 
7 (Fig. 2G)(blood-type B), that remained PCR-negative throughout the entire 
study, subsequently seroconverted eight weeks after a second subcutaneous 
inoculation of 10 µl of blood (Table 2, B IV.). 
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4.8 Microscopic examination of blood smears 
For none of the infected cats, independent of the CMt loads, were 
characteristic hemoplasma-like inclusions doubtlessly identified on blood 
smears by microscopy. 
 
4.9 Antibiotic treatment 
During marbofloxacin treatment CMt copy numbers decreased below 
detectable limits in Cats X and Y but the cats tested PCR-positive in a 
subsequent blood collection (Fig. 1). In contrast, after doxycycline treatment all 
three cats, X, Y and Z, turned persistently PCR-negative in the blood until the 
end of the study (167 days p.i. for Cats X and Y; 119 days p.i. for Cat Z). The 
nine PCR-positive recipient cats did not receive any antibiotic treatment; they 
all turned PCR-negative within 4-5 months and remained negative until the 
end of the observation period (7-10 weeks later). 
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5 Discussion 
This is the first experimental study to investigate direct transmission routes for 
feline hemoplasmas, i.e. transmission via social or aggressive contact 
between cats, using sensitive and specific real-time PCR assays. None of the 
cats exposed oronasally or orally to saliva or blood of CMt-infected cats 
became PCR-positive for CMt in blood. The same held true for subcutaneous 
inoculation of saliva. In contrast, subcutaneous exposure to infectious blood 
led to infection.  
Shedding of CMt DNA via saliva had been demonstrated in an earlier study in 
two experimentally infected cats (47). In addition in the present study, CMt 
DNA was found in saliva of all three monitored cats. Shedding started two to 
three weeks after exposure in all three cats. This is in accordance with our 
previous study (47) where we could demonstrate that shedding lasts up to 48 
and 63 days. Due to the unavailability of culture assays, it cannot be 
determined in vitro whether CMt DNA in the saliva of infected cats represented 
viable organisms. However, according to our findings CMt-positive saliva does 
not pose a major risk for infection to naïve cats. Nonetheless, a 
seroconversion was provoked in one of the cats (Cat 2) fed with CMt-positive 
saliva. Thus, in the latter cat at least CMt antigens must have been transmitted 
via saliva and minimal CMt replication below the detection limit of the PCR or 
in tissues cannot be excluded. It is unlikely that the CMt loads in the saliva 
samples were too low to result in PCR-positivity because the same copy 
number given in blood was sufficient to infect cats after subcutaneous 
inoculation even without preexisting immunosuppression.  
CMt-positive blood was found to be infectious when administered 
intravenously, intraperitoneally or subcutaneously (46 and present study). In 
contrast, oral inoculation of CMt-positive blood did not result in infection in the 
present study. In a very early study, transmission of 5 ml of blood from 
hemoplasma infected cats as determined by microscopy resulted in infection 
 17 
of the recipient cats (7). However, in our opinion it seems highly unlikely that a 
cat would be exposed to such a large volume of infectious blood under natural 
conditions. We thus did not exceed 500 µl of infectious blood collected at peak 
bacteremia in the present study to simulate a natural/physiological way.  
As a model for aggressive interactions, the subcutaneous inoculation route 
was chosen. All cats inoculated with as little as two drops (10 µl) of CMt-
positive blood became infected. Small volumes of blood of a CMt-positive cat 
could be transmitted to a recipient cat via cat bite. Moreover, this volume 
corresponds also to that reportedly consumed by Ctenocephalides felis (C. 
felis) per day during hematophagous activity (5). However, experimental 
studies of flea transmission were not conclusive so far (50, 51) and the role of 
C. felis in the transmission of hemoplasmas is still unclear. 
In accordance with our earlier study (46), CMt infection led to anemia 
particularly in the immunosuppressed cats. The cat that had received the 
highest dose of immunosuppressant (Cat Z), showed the shortest incubation 
period, the highest blood loads and the lowest PCV values among the three 
amplificatory cats. An inverse association of the CMt loads with the PCV 
values was found as had been reported earlier for two experimentally CMt 
infected cats (46). 
The differences observed in the course of the CMt infections (minimal PCV, 
maximal CMt loads, incubation period) between the amplificatory and the 
recipient cats may not only be attributed to presence of immunosuppression 
but also to the different infection route, infection dose and age of the cats. At 
this point it cannot be determined whether each of these factors by itself had a 
significant influence on the infection. However, overall it was found that the 
shorter the incubation period and the higher the CMt load, the lower the PCV 
value. This confirms that if CMt infects a cat rapidly and vigorously, the 
infection leads to significant anemia.   
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Eight of nine cats that became PCR-positive after subcutaneous CMt exposure 
showed a similar infection course: the cats turned PCR-positive within two to 
five weeks and they all seroconverted within 5 weeks p.i. and within two weeks 
after PCR-positivity in the blood. Interestingly, a somewhat different course of 
infection was observed in two cats and remarkably, these were the only two 
cats with blood-type B in the present study. One cat, Cat 2, was already 
seropositive at the time point of the subcutaneous exposure. It had 
seroconverted after the oronasal exposure to infectious saliva (see above). 
Cat 2 became later PCR-positive (day 45) after subcutaneous exposure and 
developed lower CMt peak blood loads (1.4 x 103 copies/ml) compared to the 
other eight cats (median peak loads: 5.7 x 104 copies/ml). The second blood-
type B cat, Cat 7, stayed all along PCR-negative in the blood even after 
repeated exposures. The cat seroconverted subsequently after the second 
inoculation but in the absence of PCR-positivity in the blood. While in the first 
cat, the oronasal exposure to CMt antigens and the induced immune response 
might have led to partial protection and reduced CMt loads, in the second cat 
the antibiotic treatment three weeks prior to the first CMt inoculation might 
have influenced the course of infection. Alternatively, the blood-type of the two 
cats, blood-type B, might have played a role in the susceptibility to CMt and 
infection outcome. An influence of the blood-type has been described in 
humans concerning other infections (11). The herein described course of CMt 
infection, seroconversion in the absence of detectable CMt in the peripheral 
blood, had not been described previously.  
Microscopy of blood smears as a means of diagnosis for CMt infection cannot 
be recommended which is consistent with earlier findings (40, 48). We assume 
that the insufficient detectability might be due to the low CMt blood loads (45 
and present study). They were reported to be significantly lower than Mhf 
blood loads (45). Even peak CMt loads (106 CMt/ml) calculated to only one 
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CMt cell in 103  to 104 erythrocytes. Thus, for reliable diagnosis of CMt infection 
sensitive real-time PCR must be recommended.  
The herein described serological assay based on an HspA1 fragment of Mhf 
applied in a Western blot demonstrated seroconversion in all thirteen exposed 
cats after experimental infection. Using this assay, seropositive, PCR-negative 
animals could be identified. In the cats that had received antibiotic treatment, a 
decrease in band intensity in the Western blot assay was found over time, 
while the ten cats without treatment stayed seropositive. Antibiotic treatment 
might have cleared CMt from blood and tissues, while a sequestered CMt 
infection might have led to a continuous low level stimulation of the humoral 
immune response in the untreated cats. The herein described serological 
assay may be an excellent tool to further investigate the pathogenesis of 
hemoplasma infections.   
In conclusion, our results indicate that social contact, such as sharing of food 
dishes or grooming, with CMt-positive cats does not pose a risk of infection to 
naïve cats. However, our hypothesis was partially confirmed insofar as direct 
transmission of CMt via aggressive interaction (cat bite) may occur, even if the 
recipient cat is exposed to a minimal volume of infectious blood.  
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6 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Intraperitoneal (i.p.) ,Candidatus M. turicensis’ (CMt) infection in the three amplificatory 
SPF cats, Cat X (A), Y (B), and Z (C). Kinetics of CMt blood loads (left y-axis, black squares), PCV 
values (right y-axis, open squares), shedding in saliva (triangle beneath x-axis) and serology results 
as determined by Western blot (circles beneath x-axis) throughout the time course of the CMt infection 
(x-axis, days p.i.). Blood loads are given in log copy numbers of DNA template per ml of blood. PCV is 
given as a percentage. Saliva samples were analyzed by real-time PCR: PCR-positive swabs are 
indicated by black triangles; negative swabs are depicted by open triangles. Western blot positive and 
negative serum samples are shown by black and open circles, respectively. From day 41 to day 50 
p.i., Cats X and Y were treated with marbofloxacin (white square marked “M”) Treatment was then 
switched for 14 days to doxycycline (gray square marked “D”). Cat Z was treated with doxycycline 
from day 41 to day 54 p.i. 
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FIGURE 2. Results of transmission studies in ten SPF recipient cats after subcutaneous (s.c.) CMt 
inoculation experiments A V. (group A; cats 1 to 5; A to E) and B III. (group B; cats 6 to 10; F to K), 
respectively. Kinetics of CMt blood loads (left y-axis, black squares), PCV values (right y-axis, open 
squares) and serology results as determined by Western blot (circles beneath x-axis) throughout the 
time course of the CMt infection (x-axis, days after exposure). Blood loads are given in log copy 
numbers of DNA template per ml of blood. The PCV is given as a percentage. Western blot positive 
and negative serum samples are shown by black and open circles, respectively. Cat 7 (B) received a 
second subcutaneous inoculation of CMt (Table 1, exposure B IV.) at day 103 as indicated by the 
black arrow. 
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FIGURE 3. Comparison of experimental infections of CMt peak blood loads (A), duration between CMt 
inoculation and the first PCR-positive blood result (B), and minimum PCV values (C) in the 
amplificatory (intraperitoneal exposure; Cats X, Y, Z; n = 3) and the recipient cats (subcutaneous 
exposure; groups A and B; n = 9). Only cats that became PCR-positive were included in the analyses. 
Intraperitoneally infected cats had significantly higher CMt peak blood loads (A), lower minimum PCV 
values (B) and more rapidly became PCR-positive (C) than subcutaneously infected cats (p-values 
calculated by the Mann-Whitney U-test indicated in the Figure). 
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FIGURE 4. Correlation analyses of anemia and CMt loads. Minimum PCV values were negatively 
correlated with peak CMt blood loads (A) and significantly positively correlated with duration between 
CMt exposure and the first PCR-positive result (B). The peak CMt loads were significantly negatively 
correlated with the incubation period (C). Correlation was determined by Spearman rank correlation 
test (r and p values indicated in the Figure). 
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Figure 5. Western blot analyses of 16 experimentally hemoplasma infected cats and 5 SPF cats using 
recombinant Mhf HspA1 as antigen. A) Western blot analyses of animals infected with different 
hemotropic Mycoplasmas (1 = cat infected with Mhf; 2 = cat infected with CMhm; 3 = cat infected with 
CMt; 4 – 8 = SPF cats), B) sera of group A and B and amplificatory cats collected prior to exposure. C) 
sera of group A and B and amplificatory cats collected post-exposure (5 to 11 weeks after inoculation 
of CMt containing blood). M = Marker; stripes 1 to 5 = cats of group A; stripes 6 to 10 = cats of group 
B, stripes 11 to 13 = Cat X, Y, Z. Seroconversion occurred as early as three weeks p.i., but in one cat 
only eight weeks after CMt inoculation. Arrow at 33.6 kDa.  
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TABLE 1. Experimental setup of CMt transmission studies: groups and 
numbers of cats, experiment, protocol of immunosuppression, inoculum 
(infectious saliva or blood) and inoculation route and monitoring period. 
 
Group  
of Cats 
Experiment Immuno-
suppression 
Number
of cats 
Inoculum 
(total copies 
of CMt) 
Inoculation 
route 
Monitoring  
period  
(days) 
Group A I. Transmission by 
saliva 
 5 2 ml saliva  
(8 x 102 
copies) 
Oronasal 31 
 II. Transmission by 
saliva, immuno-
suppression 
5 mg/kg/d for 
8 days; 2,5 
mg/kg/d for 
29 days 
51 6 ml saliva 
(7 x 103 
copies) 
Oronasal 43 
 III. Transmission by 
blood 
 51 63 µl blood 
(8 x 103 
copies) 
Oral 71 
 IV. Transmission by 
blood 
 51 500 µl blood 
(4 x 105 
copies) 
Oral 62 
 V. Transmission by 
blood 
 51 50 µl blood 
(6 x 103 
copies) 
Subcutaneous 159 
Group B I. Transmission by 
saliva 
 5 100 µl saliva 
(1 x 102 
copies) 
Subcutaneous 44 
 II. Transmission by 
saliva, immuno-
suppression 
5 mg/kg/d for 
8 days; 2,5 
mg/kg/d for 
14 days 
52 2 x 200 µl 
saliva 
(1 x 103 
copies) 
Subcutaneous 29 
 
 
III. Transmission by 
blood 
 52 10 µl blood 
(1 x 103 
copies) 
Subcutaneous 99 
 IV. Transmission by 
blood 
 12  
(Cat 7) 
10 µl blood 
(1 x 103 
copies) 
Subcutaneous 62 
1: same cats as used in experiment A I. 2: same cats as used in experiment B I. 
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TABLE 2. Outcome of CMt transmission studies (blood real-time PCR from 
blood and serology results) in groups and experiments described in Table 1. 
Group/ 
Experiment Cat 1 Cat 2 Cat 3 Cat 4 Cat 5 
 PCR Serology PCR Serology PCR Serology PCR Serology PCR Serology
A I) - - - - - - - - - - 
A II) - - - + - - - - - - 
A III) - - - + - - - - - - 
A IV) - - - + - - - - - - 
A V) + + + + + + + + + + 
           
 Cat 6 Cat 7 Cat 8 Cat 9 Cat10 
 PCR Serology PCR Serology PCR Serology PCR Serology PCR Serology
B I) - - - - - - - - - - 
B II) - - - - - - - - - - 
B III) + + - - + + + + + + 
B IV) nt nt - + nt nt nt nt nt nt 
nt = not tested 
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